Insulet (PODD) FY Conference June 10, 2025 09:20 AM ET Speaker0 Well, good morning, everyone. We'll, we'll go ahead and get started here just to make a quick housekeeping announcement that, presentations are not open to members, of the press. With that, I'm very pleased to welcome Anna Maria Chadwick, Executive Vice President and Chief Financial Officer for Insulet. As with all these sessions, if there are questions, feel free to raise your hand, and we'll get a mic over to you so that people participating ...

Insulet Corporation (PODD) has witnessed strong momentum in the past year. Shares of the company have risen 78.5% compared with 7.3% growth of the industry during the same time frame. The S&P 500 Composite has increased 9.3%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Insulet develops, manufactures and markets the Omnipod System — an innovative, discreet and easy-to-use continuous insulin de ...

Insulet TodayPODDInsulet$314.46 -2.21 (-0.70%) 52-Week Range$160.19▼$323.00P/E Ratio54.31Price Target$306.53Add to WatchlistInsulet Corporation’s NASDAQ: PODD recent outperformance has caught investors' attention and has earned it a designation as a top performer on the S&P 500. The medical device company, known for its innovative tubeless insulin pump system, saw its stock price climb by over 24% in the past five days. This jump in Insulet’s stock price has been driven by multiple catalyst’s including a r ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Insulet Corporation (PODD) reported first-quarter 2025 adjusted earnings per share (EPS) of $1.02, up 39.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 25.9%.GAAP EPS was 50 cents, down 32.4% from the year-ago quarter’s figure.PODD’s Q1 RevenuesRevenues totaled $569 million, which beat the Zacks Consensus Estimate by 4.9%. The top line jumped 28.8% year over year and 29.8% at constant exchange rate or CER. CER growth exceeded the company’s high end of the gui ...

Insulet Corporation PODD reported first-quarter adjusted earnings of $1.02 per share, beating the consensus of 80 cents.The automated insulin delivery technology maker reported sales of $569 million, up 28.8% year over year (29.8% in constant currency), beating the consensus of $543.4 million, exceeding the high end of the company’s guidance range of 25% in constant currency.Total Omnipod revenue reached $554.1 million, an increase of 28.0%, or 29.0% in constant currency.U.S. Omnipod revenue of $401.7 milli ...

Insulet (PODD) reported $569 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 28.8%. EPS of $1.02 for the same period compares to $0.73 a year ago.The reported revenue represents a surprise of +4.96% over the Zacks Consensus Estimate of $542.11 million. With the consensus EPS estimate being $0.81, the EPS surprise was +25.93%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

Revenue Growth - Total revenue for Q1 2025 increased by $127.3 million, or 28.8%, to $569.0 million compared to $441.7 million in Q1 2024, with constant currency revenue growth of 29.8%[83] - U.S. Omnipod revenue rose by $84.0 million, or 26.4%, to $401.7 million in Q1 2025, driven by higher sales volume and customer base growth[84] - International Omnipod revenue increased by $37.1 million, or 32.2%, to $152.4 million in Q1 2025, with a 36.1% increase in constant currency, primarily due to higher volumes from new customers[86] Profitability and Margins - Gross margin improved to 71.9% in Q1 2025, up from 69.5% in Q1 2024, attributed to better manufacturing and supply chain efficiencies[90] - Adjusted EBITDA for Q1 2025 was $133.9 million, compared to $89.2 million in Q1 2024, reflecting improved operational performance[99] - Adjusted EBITDA is used as a supplemental measure for assessing performance, reflecting net income plus significant expenses and transactions[102] Expenses - Research and development expenses for Q1 2025 increased by $9.4 million, or 18.7%, to $59.6 million, reflecting investments in Omnipod and pipeline products[92] - Selling, general and administrative expenses rose by $60.9 million, or 30.5%, to $260.6 million in Q1 2025, mainly due to headcount additions for customer support and business growth[93] Cash Flow and Capital Structure - Free cash flow for the three months ended March 31, 2025, was $51.5 million, down from $65.5 million in the same period of 2024[122] - Cash and cash equivalents increased to $1,283.1 million as of March 31, 2025, compared to $953.4 million at December 31, 2024[107] - Total debt, net, rose to $1,695.4 million as of March 31, 2025, from $1,379.9 million at December 31, 2024, with a debt-to-total capital ratio of 56%[107] - Net cash provided by financing activities was $277.8 million for the three months ended March 31, 2025, compared to a cash outflow of $14.1 million in the same period of 2024[117] Investments and Expenditures - The company entered into a purchase agreement for semiconductor chips worth $71.6 million in 2025[105] - Capital expenditures decreased to $12.3 million for the three months ended March 31, 2025, from $22.1 million in the same period of 2024[115] - Investments in developed software increased to $3.4 million for the three months ended March 31, 2025, compared to $1.9 million in the same period of 2024[116] Shareholder Actions - The company authorized a share repurchase program of up to $125 million through December 31, 2026, to offset dilution from stock-based compensation[111] - The company repurchased $420 million in principal of its Convertible Senior Notes in March and April 2025[108] Future Outlook - The company expects strong U.S. revenue growth for the full year 2025, driven by the recurring revenue model and continued volume growth of Omnipod 5[85] - The company plans to launch Omnipod 5 in nine additional countries, enhancing international market presence and regulatory efforts[78] Taxation - The effective tax rate for Q1 2025 was 26.4%, significantly higher than 6.2% in Q1 2024, primarily due to non-deductible charges and changes in deferred tax asset valuation[97]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $569 million, representing a 30% year-over-year growth, driven by a 29% increase in total Omnipod growth [21][22] - Gross margin improved to 71.9%, up 240 basis points year-over-year, while adjusted operating margin was 16.4% [34][35] - The company raised its gross margin guidance for the full year to approximately 71% despite an estimated 50 basis point impact from tariffs [43][44] Business Line Data and Key Metrics Changes - U.S. Omnipod revenue grew 26%, exceeding guidance, with strong demand for Omnipod five contributing to this growth [26][27] - New customer starts in the U.S. for Type one and Type two diabetes increased, with over 30% of new starts being Type two [20][21] - International revenue grew 36% above guidance, driven by strong demand for Omnipod five and customer base expansion [31][32] Market Data and Key Metrics Changes - The U.S. market saw a significant increase in healthcare providers prescribing Omnipod five, with nearly 25,000 HCPs now writing scripts, up over 20% from the previous year [30][31] - The company launched Omnipod five in Canada and Switzerland, bringing the total number of international market launches to 13 [32][33] - The international market for Type one diabetes is approximately 3.5 million people, with only 20% to 25% penetration, indicating significant growth potential [99] Company Strategy and Development Direction - The company aims to expand its revenue from $2 billion to $4 billion to $6 billion by focusing on Type one and Type two markets and advancing globalization [12][53] - Strategic priorities include advancing innovation, driving growth in U.S. Type one and Type two populations, and expanding internationally [15][40] - The leadership emphasizes the importance of brand activation and direct-to-consumer strategies to enhance engagement and retention [13][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing a strong first quarter performance and a robust pipeline of innovation [48][49] - The leadership transition is seen as timely, with the new CEO bringing a focus on operational excellence and strategic vision [8][10] - The company anticipates continued strong growth in new customer starts and is optimistic about the adoption of Omnipod five in both Type one and Type two markets [40][41] Other Important Information - The company ended the quarter with approximately $1.3 billion in cash and a $500 million credit facility available, enhancing financial flexibility [37][36] - The board authorized a stock repurchase program of up to $125 million to offset dilution from stock-based compensation [46] Q&A Session Summary Question: What excites you about the role at Insulet and your vision for the business? - The new CEO expressed passion for the diabetes space and highlighted the company's strong momentum and unique position in the market [54][56] Question: Will there be a focus on top-line growth at the expense of margin expansion? - The CEO reassured that the business strategy remains intact, with continued focus on both growth and margin improvement [62] Question: What is the status of the Type two pump adoption in the U.S.? - The management reported strong progress in the Type two launch, with over 30% of new customer starts coming from this segment [65] Question: Can you confirm the strong new start growth in both the U.S. and internationally? - Management confirmed significant strength in new customer starts, both sequentially and year-over-year, driven by the differentiation of Omnipod five [74][75] Question: What are the expectations for gross and operating margin expansion in the coming years? - The management expressed confidence in maintaining industry-leading gross margins while continuing to invest in growth opportunities [78][81] Question: How is the direct-to-consumer advertising performing? - The company reported higher conversion rates from direct-to-consumer advertising efforts, indicating effective engagement strategies [109]